MCID: PNT038
MIFTS: 44

Peanut Allergy malady

Categories: Immune diseases

Aliases & Classifications for Peanut Allergy

Aliases & Descriptions for Peanut Allergy:

Name: Peanut Allergy 12 14
Allergy to Peanuts 12 69
Peanut Allergic Reaction 12
Peanut Hypersensitivity 42
Allergies Peanut 52

Classifications:



External Ids:

Disease Ontology 12 DOID:4378
MeSH 42 D021183
SNOMED-CT 64 213021008 91935009
UMLS 69 C0559470

Summaries for Peanut Allergy

Disease Ontology : 12 A food allergy that is an allergy or hypersensitivity to dietary substances from peanuts causing an overreaction of the immune system which in a small percentage of people may lead to severe physical symptoms.

MalaCards based summary : Peanut Allergy, also known as allergy to peanuts, is related to facial arteriovenous malformation and stocco dos santos syndrome. An important gene associated with Peanut Allergy is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Budesonide and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and skin, and related phenotypes are digestive/alimentary and respiratory system

Wikipedia : 71 Peanut allergy is a type of food allergy to peanuts. It is different from nut allergies. Physical... more...

Related Diseases for Peanut Allergy

Diseases related to Peanut Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
id Related Disease Score Top Affiliating Genes
1 facial arteriovenous malformation 10.3 FLG IGHE
2 stocco dos santos syndrome 10.3 IFNG IGHE
3 deep dermatophytosis 10.3 HLA-DQB1 IFNG
4 papillary squamous carcinoma 10.3 FLG IGHE
5 israeli tick typhus 10.3 IFNG IL13
6 variola minor 10.2 FLG IFNG
7 caplan's syndrome 10.2 HLA-DRB1 IFNG
8 crustacean allergy 10.2 IFNG IL13
9 apple allergy 10.2 HLA-DQB1 HLA-DRB1
10 hemoglobin d disease 10.2 HLA-DQB1 HLA-DRB1
11 bilateral parasagittal parieto-occipital polymicrogyria 10.2 HLA-DQB1 HLA-DRB1
12 immune deficiency, familial variable 10.2 HLA-DQB1 HLA-DRB1
13 lin-gettig syndrome 10.2 HLA-DQB1 HLA-DRB1
14 spastic diplegia 10.2 IFNG IL13
15 midline interhemispheric variant of holoprosencephaly 10.2 HLA-DQB1 HLA-DRB1
16 bone peripheral neuroepithelioma 10.2 FLG IL13
17 autosomal dominant intermediate charcot-marie-tooth 10.2 HLA-DQB1 HLA-DRB1
18 renal agenesis meningomyelocele mullerian defect 10.2 HLA-DQB1 HLA-DRB1
19 lyme disease - neurological complications 10.2 HLA-DQB1 HLA-DRB1
20 gastroschisis abdominal wall defects, included 10.2 AHR IFNG
21 asymptomatic neurosyphilis 10.2 IFNG IL10
22 learning disability 10.2 HLA-DQB1 HLA-DRB1
23 linear lichen planus 10.2 HLA-DQB1 HLA-DRB1
24 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.2 IFNG IL10
25 night blindness 10.2 HLA-DQB1 HLA-DRB1
26 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.2 HLA-DQB1 IFNG
27 tungiasis 10.2 IFNG IL10
28 acute gonococcal prostatitis 10.2 IFNG IL13
29 neonatal antiphospholipid syndrome 10.2 HLA-DQB1 HLA-DRB1
30 papillary adenocarcinoma 10.2 IL10 IL13
31 ciliary discoordination, due to random ciliary orientation 10.2 IFNG IL10
32 plantar wart 10.2 IFNG IL10
33 centronuclear myopathy 5 10.2 IFNG IL10
34 tarsal tunnel syndrome 10.2 IL10 IL13
35 discharging ear 10.2 IFNG IL10
36 goat milk allergy 10.1 IL10 IL13
37 osteodysplasty precocious of danks mayne and kozlowski 10.1 IFNG IL10
38 parkinson disease 11 10.1 IFNG IL10
39 distal trisomy 14q 10.1 HLA-DQB1 HLA-DRB1 IFNG
40 clostridium difficile colitis 10.1 HLA-DQB1 HLA-DRB1 IFNG
41 bickerstaff brainstem encephalitis 10.1 HLA-DQB1 HLA-DRB1 IFNG
42 lepromatous leprosy 10.1 IFNG IL10
43 balkan nephropathy 10.1 FLG IFNG IL10
44 parasitic protozoa infectious disease 10.1 FLG IFNG IL10
45 glucocorticoid resistance 10.1 IFNG IGHE IL13
46 rosacea 10.1 IFNG IL10
47 oromandibular dystonia 10.1 HLA-DQB1 HLA-DRB1
48 isolated klippel-feil syndrome 10.1 AHR IFNG IGHE
49 solitary bone cyst 10.1 FLG IFNG IL10
50 cockayne syndrome, type b 10.1 IFNG IGHE IL10

Graphical network of the top 20 diseases related to Peanut Allergy:



Diseases related to Peanut Allergy

Symptoms & Phenotypes for Peanut Allergy

MGI Mouse Phenotypes related to Peanut Allergy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.35 AHR HLA-DQB1 IFNG IL10 IL13
2 respiratory system MP:0005388 9.1 AHR CD14 HLA-DQB1 IFNG IL10 IL13

Drugs & Therapeutics for Peanut Allergy

Drugs for Peanut Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4 51333-22-3 63006 5281004
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Petrolatum Approved Phase 4 8009-03-8
6
decanoic acid Experimental Phase 4 334-48-5 2969
7 Anti-Allergic Agents Phase 4,Phase 2,Phase 3,Phase 1
8 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
10 Autonomic Agents Phase 4,Phase 2,Phase 3
11 Bronchodilator Agents Phase 4,Phase 2,Phase 3
12 Dermatologic Agents Phase 4,Phase 2,Phase 3
13
Fluticasone Phase 4,Phase 2,Phase 3 90566-53-3, 80474-14-2 62924 22833648
14 glucocorticoids Phase 4,Phase 2,Phase 3
15 Hormone Antagonists Phase 4,Phase 2,Phase 3
16 Hormones Phase 4,Phase 2,Phase 3
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
18 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
19 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1
20 Neurotransmitter Agents Phase 4,Phase 2
21 Central Nervous System Stimulants Phase 4
22 Cholinergic Agents Phase 4
23 Nicotinic Agonists Phase 4
24 Progestins Phase 4
25 Antifungal Agents Phase 4
26 Anti-Infective Agents Phase 4
27 Emollients Phase 4
28 Olive Nutraceutical Phase 4
29 Soy Bean Nutraceutical Phase 4,Phase 2,Phase 3
30 Antibodies Phase 3,Phase 1,Phase 2
31 Immunoglobulin E Phase 3,Phase 1,Phase 2
32 Immunoglobulins Phase 3,Phase 1,Phase 2
33
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
34
Ketotifen Approved Phase 2 34580-14-8, 34580-13-7 3827
35
Omalizumab Approved, Investigational Phase 1, Phase 2 242138-07-4
36
Glycerol Approved, Experimental Phase 1, Phase 2 56-81-5 753
37 Antipruritics Phase 2
38 Histamine Antagonists Phase 2
39 Histamine H1 Antagonists Phase 2
40
Histamine Phosphate Phase 2 51-74-1 65513
41 Protective Agents Phase 1, Phase 2
42 Pharmaceutical Solutions Phase 2,Phase 1
43
Phenol Approved, Experimental Phase 1 108-95-2 996
44 Vaccines Phase 1
45
Cefpodoxime Approved, Vet_approved 82619-04-3, 80210-62-4 6335986
46
Nitric Oxide Approved 10102-43-9 145068
47
Benzocaine Approved 1994-09-7, 94-09-7 2337
48 tannic acid Approved, Nutraceutical
49
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
50
Resveratrol Experimental, Investigational 501-36-0, 955365-80-7 24856436 445154

Interventional clinical trials:

(show top 50) (show all 108)
id Name Status NCT ID Phase
1 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Unknown status NCT01846962 Phase 4
2 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Recruiting NCT01966640 Phase 4
3 Progesterone and Brain Imaging Study Recruiting NCT01954966 Phase 4
4 Early Intervention With Lipid-Rich Barrier Cream in Infants at High Risk of Atopy Not yet recruiting NCT03089476 Phase 4
5 Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers Unknown status NCT02046083 Phase 2, Phase 3
6 PALISADE Follow-on Study (ARC004) Recruiting NCT02993107 Phase 3
7 Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Recruiting NCT03126227 Phase 3
8 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3
9 Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Active, not recruiting NCT02635776 Phase 3
10 Safety Study of Viaskin Peanut to Treat Peanut Allergy Active, not recruiting NCT02916446 Phase 3
11 Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy Active, not recruiting NCT02636699 Phase 3
12 Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children Enrolling by invitation NCT03013517 Phase 3
13 Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization Unknown status NCT01625715 Phase 2
14 The Effect of Extrinsic Factors on Food Allergy Unknown status NCT01429896 Phase 2
15 Therapeutic Effect of Chinese Herbal Medicine on Food Allergy Unknown status NCT00602160 Phase 2
16 Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy Completed NCT00932282 Phase 1, Phase 2
17 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Completed NCT01084174 Phase 1, Phase 2
18 Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy Completed NCT01675882 Phase 2
19 Oral Immunotherapy for Peanut Allergy (PMIT) Completed NCT00597675 Phase 2
20 Epicutaneous Immunotherapy in Peanut Allergy in Children Completed NCT01197053 Phase 2
21 Omalizumab in the Treatment of Peanut Allergy Completed NCT00949078 Phase 2
22 A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial Completed NCT00580606 Phase 1, Phase 2
23 Xolair Enhances Oral Desensitization in Peanut Allergic Patients Completed NCT01290913 Phase 1, Phase 2
24 Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study Completed NCT00932828 Phase 1, Phase 2
25 A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g Completed NCT00382148 Phase 2
26 Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Completed NCT01955109 Phase 2
27 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT Completed NCT01987817 Phase 2
28 Persistence of Oral Tolerance to Peanut Completed NCT01366846 Phase 2
29 Promoting Tolerance to Peanut in High-Risk Children Completed NCT00329784 Phase 2
30 Mechanisms of Desensitization During Peanut Oral Immunotherapy Completed NCT01814241 Phase 2
31 A Study of Sublingual Immunotherapy in Peanut-allergic Children Completed NCT00597727 Phase 2
32 Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy Recruiting NCT02920021 Phase 2
33 Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study Recruiting NCT02149719 Phase 2
34 FARE Peanut SLIT and Early Tolerance Induction Recruiting NCT02304991 Phase 2
35 E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy Recruiting NCT02879006 Phase 2
36 Oral Immunotherapy (OIT) for Peanut Allergy Active, not recruiting NCT00815035 Phase 2
37 Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy Active, not recruiting NCT02402231 Phase 2
38 Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Active, not recruiting NCT01373242 Phase 1, Phase 2
39 Peanut Oral Immunotherapy in Children Active, not recruiting NCT01867671 Phase 2
40 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Active, not recruiting NCT01904604 Phase 2
41 The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery Active, not recruiting NCT02103270 Phase 2
42 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial Active, not recruiting NCT01781637 Phase 1, Phase 2
43 Tolerance Following Peanut Oral Immunotherapy Active, not recruiting NCT01750879 Phase 1, Phase 2
44 Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using (CPNA) Peanut OIT Safety Follow-On Study Active, not recruiting NCT02198664 Phase 2
45 The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy Suspended NCT01897077 Phase 1, Phase 2
46 Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults Terminated NCT01274429 Phase 1, Phase 2
47 A Safety and Efficacy Study of Xolair in Peanut Allergy Terminated NCT00086606 Phase 2
48 Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy Withdrawn NCT01451450 Phase 2
49 Peanut Allergy Oral Immunotherapy Desensitization Unknown status NCT01601522 Phase 1
50 HAL-MPE1 First-in-human Completed NCT02163018 Phase 1

Search NIH Clinical Center for Peanut Allergy

Cochrane evidence based reviews: peanut hypersensitivity

Genetic Tests for Peanut Allergy

Anatomical Context for Peanut Allergy

MalaCards organs/tissues related to Peanut Allergy:

39
Testes, T Cells, Skin

Publications for Peanut Allergy

Articles related to Peanut Allergy:

(show top 50) (show all 80)
id Title Authors Year
1
Guidelines for Children With Peanut Allergy. ( 28030748 )
2017
2
Addendum guidelines for the prevention of peanut allergy in the United States: Summary of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. ( 28054718 )
2017
3
Evolution of Guidelines on Peanut Allergy and Peanut Introduction in Infants: A Review. ( 27820622 )
2017
4
Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. ( 28065278 )
2017
5
Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-Sponsored Expert Panel. ( 28054723 )
2017
6
Immunotherapy using algal-produced Ara h 1 core domain suppresses peanut allergy in mice. ( 26801740 )
2016
7
Genomewide association study of peanut allergy reproduces association with amino acid polymorphisms in HLA-DRB1. ( 27883235 )
2016
8
Introduction of peanuts in younger siblings of children with peanut allergy: a prospective, double-blinded assessment of risk, of diagnostic tests, and an analysis of patient preferences. ( 27291651 )
2016
9
Which test is best for diagnosing peanut allergy in South African children with atopic dermatitis? ( 26821907 )
2016
10
Reproducibility of serum IgE, Ara h2 skin prick testing and fraction of exhaled nitric oxide for predicting clinical peanut allergy in children. ( 27499764 )
2016
11
Component-Resolved Diagnosis of Peanut Allergy and Its Possible Origins of Sensitization in China. ( 27240834 )
2016
12
Clinical Significance of Component Allergens in Fagales Pollen-Sensitized Peanut Allergy in Korea. ( 27582401 )
2016
13
Enhanced Prophylactic and Therapeutic Effects of Polylysine-Modified Ara h 2 DNA Vaccine in a Mouse Model of Peanut Allergy. ( 28049187 )
2016
14
Low dose immunotherapy in very young children to treat peanut allergy. ( 27599211 )
2016
15
Calculating the effect of population-level implementation of the Learning Early About Peanut Allergy (LEAP) protocol to prevent peanut allergy. ( 26874368 )
2016
16
Early Peanut Introduction and Prevention of Peanut Allergy in High-Risk Infants: Consensus Communication. ( 26760846 )
2016
17
Safety of epicutaneous immunotherapy for the treatment of peanut allergy: AA phase 1 study using the Viaskin patch. ( 26920463 )
2016
18
Lupin and Other Potentially Cross-Reactive Allergens in Peanut Allergy. ( 27873194 )
2016
19
Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. ( 27464222 )
2016
20
Tragic Outcome of Peanut Allergy. ( 27567655 )
2016
21
A lurking threat: transfer of peanut allergy through peripheral blood stem cell transplantation. ( 26904156 )
2016
22
Peanut allergy, anaphylaxis, adrenaline and exacerbations of asthma. ( 27893943 )
2016
23
Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. ( 27372563 )
2016
24
The IgE and basophil responses to Ara h 2 and Ara h 6 are good predictors of peanut allergy in children. ( 27516216 )
2016
25
Oral immunotherapy for peanut allergy induces eosinophilic esophagitis: three pediatric case reports. ( 26888330 )
2016
26
Peanut Allergy: New Developments and Clinical Implications. ( 27039393 )
2016
27
Diagnostic Value of Specific IgE to Peanut and Ara h 2 in Korean Children with Peanut Allergy. ( 26739409 )
2016
28
Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. ( 28065802 )
2016
29
Peanut allergy as a family project: social relations and transitions in adolescence. ( 28000310 )
2016
30
Cor a 14 is the superior serological marker for hazelnut allergy in children, independent of concomitant peanut allergy. ( 26666993 )
2016
31
Prevalence and factors associated to peanut allergy in Mexican school children. ( 27475774 )
2016
32
The diagnostic value of component-resolved diagnostics in peanut allergy in children attending a Regional Paediatric Allergology Clinic. ( 27255511 )
2016
33
Omalizumab facilitates rapid oral desensitization for peanut allergy. ( 27609658 )
2016
34
Peanut allergy and isotretinoin. ( 27480215 )
2016
35
Peanut allergy in Mexican children: what is the effect of age at first consumption? ( 26996112 )
2016
36
Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. ( 27609653 )
2016
37
Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. ( 26942922 )
2016
38
Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy. ( 27130858 )
2016
39
Understanding the feasibility and implications of implementing early peanut introduction for prevention of peanut allergy. ( 27260320 )
2016
40
Does Exposing Infants to Peanut Products Influence the Risk of a Peanut Allergy? ( 27343973 )
2016
41
Isotretinoin treatment in a patient with known peanut allergy and positive IgE test results for soybean. ( 27670093 )
2016
42
Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. ( 28091362 )
2016
43
The prevalence, natural history and time trends of peanut allergy over the first 10A years of life in two cohorts born in the same geographical location 12A years apart. ( 27434312 )
2016
44
Individually dosed omalizumab: an effective treatment for severe peanut allergy. ( 27883239 )
2016
45
WITHDRAWN: Introduction to the Addendum Guidelines for the Prevention of Peanut Allergy in the United States. ( 27986372 )
2016
46
A humanized mouse model of anaphylactic peanut allergy. ( 27417025 )
2016
47
Oral Immunotherapy for Management of Peanut Allergy in Spanish Children. ( 27326996 )
2016
48
Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial: a critical appraisal. ( 26769642 )
2015
49
Urgent information on peanut allergy: New evidence from the LEAP study. ( 26775304 )
2015
50
Early introduction of peanut to infants at high allergic risk can reduce peanut allergy at age 5 years. ( 26385490 )
2015

Variations for Peanut Allergy

Expression for Peanut Allergy

Search GEO for disease gene expression data for Peanut Allergy.

Pathways for Peanut Allergy

Pathways related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CCL22 CD14 HLA-DQB1 HLA-DRB1 IFNG IGHE
2
Show member pathways
13.09 CCL22 HLA-DQB1 HLA-DRB1 IFNG IGHE IL10
3
Show member pathways
12.69 HLA-DQB1 HLA-DRB1 IFNG IL10 IL13
4
Show member pathways
12.62 HLA-DQB1 HLA-DRB1 IFNG IL13
5
Show member pathways
12.45 HLA-DQB1 HLA-DRB1 IFNG IGHE IL10
6 12.14 HLA-DQB1 HLA-DRB1 IFNG IL10
7
Show member pathways
12.08 HLA-DQB1 HLA-DRB1 IFNG IL10
8
Show member pathways
12.04 IFNG IL10 IL13
9
Show member pathways
11.99 IFNG IL10 IL13
10 11.98 CD14 HLA-DQB1 HLA-DRB1
11
Show member pathways
11.97 AHR HLA-DQB1 HLA-DRB1 IFNG IL10 IL13
12 11.91 CD14 HLA-DQB1 HLA-DRB1 IFNG IL10
13 11.84 CD14 IFNG IL10
14 11.75 CD14 HLA-DQB1 HLA-DRB1
15 11.74 CD14 IFNG IL10
16 11.73 CCL22 IGHE IL10 IL13
17 11.71 HLA-DQB1 HLA-DRB1 IFNG
18 11.62 CD14 IFNG IL10
19 11.53 AHR IFNG IL10 IL13
20 11.48 HLA-DQB1 HLA-DRB1 IL10
21 11.39 CCL22 IL10 IL13
22 11.19 IFNG IL10
23 11.18 CD14 IL10
24 11.16 AHR IFNG IL13
25 11.13 CCL22 IFNG IL10 IL13
26 11.08 HLA-DRB1 IFNG IL13
27 11.04 CCL22 IL10 IL13
28 11 IFNG IL10 IL13
29 10.4 HLA-DRB1 IFNG IL10 IL13

GO Terms for Peanut Allergy

Cellular components related to Peanut Allergy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 9.43 CD14 HLA-DQB1 HLA-DRB1
2 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.16 HLA-DQB1 HLA-DRB1
3 external side of plasma membrane GO:0009897 9.02 CD14 HLA-DRB1 IFNG IGHE IL13
4 MHC class II protein complex GO:0042613 8.96 HLA-DQB1 HLA-DRB1

Biological processes related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.76 IFNG IGHE IL10
2 inflammatory response GO:0006954 9.76 CCL22 CD14 IL10 IL13
3 response to lipopolysaccharide GO:0032496 9.74 CD14 IL10 IL13
4 T cell receptor signaling pathway GO:0050852 9.7 HLA-DQB1 HLA-DRB1 IFNG
5 cellular response to lipopolysaccharide GO:0071222 9.67 CD14 IFNG IL10
6 negative regulation of T cell proliferation GO:0042130 9.59 HLA-DRB1 IL10
7 positive regulation of cytokine secretion GO:0050715 9.58 CD14 IL10
8 negative regulation of endothelial cell apoptotic process GO:2000352 9.56 IL10 IL13
9 negative regulation of interferon-gamma production GO:0032689 9.55 HLA-DRB1 IL10
10 defense response to protozoan GO:0042832 9.54 IFNG IL10
11 negative regulation of growth of symbiont in host GO:0044130 9.51 IFNG IL10
12 interferon-gamma-mediated signaling pathway GO:0060333 9.5 HLA-DQB1 HLA-DRB1 IFNG
13 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.48 HLA-DQB1 HLA-DRB1
14 response to molecule of bacterial origin GO:0002237 9.43 CD14 IL10
15 positive regulation of macrophage activation GO:0043032 9.4 IL10 IL13
16 positive regulation of MHC class II biosynthetic process GO:0045348 9.37 IFNG IL10
17 antigen processing and presentation GO:0019882 9.33 HLA-DQB1 HLA-DRB1 IFNG
18 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.26 HLA-DQB1 HLA-DRB1
19 immune response GO:0006955 9.17 CCL22 HLA-DQB1 HLA-DRB1 IFNG IGHE IL10
20 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.96 HLA-DQB1 HLA-DRB1

Molecular functions related to Peanut Allergy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.16 HLA-DQB1 HLA-DRB1
2 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DRB1
3 cytokine activity GO:0005125 8.92 CCL22 IFNG IL10 IL13

Sources for Peanut Allergy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....